-

Agilent Announces New, Innovative 7850 ICP-MS System

Smart functions and tools optimize productivity and efficiency

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a new ICP-MS instrument, the Agilent 7850 ICP-MS System, that provides new smart tools to minimize common time traps that can affect ICP-MS analysis workflows.

Building on decades of innovation, the 7850 ICP-MS combines market-leading performance with new smart software features that bring advanced capabilities to the routine ICP-MS laboratory. The new 7850 provides solutions that enable customers to be more productive and efficient while ensuring high quality results.

“The biggest impact of this new system will be in helping our customers avoid common time traps that can result in wasted time, higher costs, lower productivity, and ultimately staff stress and potential turnover,” said Keith Bratchford, vice president, and general manager, Agilent Spectroscopy. “The smart tools and streamlined workflows of the 7850 simplify ICP-MS analysis, assisting customers in each step of their typical sample analysis.”

“These smart features are particularly helpful for less experienced users who are often tasked with operating the ICP-MS in small- to medium-sized contract testing labs,” Bratchford added.

The costs to a lab that fails to recognize or address common time traps are not just limited to lost time and revenue. Unnecessary method setup steps, instrument checks, manual data reviews, and the need for sample reanalysis also place more pressure on busy lab staff. This workload can impact sample turnaround time and the quality of the results that customers expect—putting a laboratory’s reputation at risk.

The 7850 uses a configuration that is optimized to handle the range of sample types measured in typical ICP-MS applications while ensuring data is free from common sources of error. Smart tools help customers through the initial setup of the instrument and required methods, and guides users through the typical ICP-MS workflow that is used to measure sample batches. Smart functions also assist with data review, eliminating the need for an ICP-MS expert to perform the important step of verifying data quality.

The new 7850 is the smart way to ensure fast setup and streamlined analysis for great results in typical ICP-MS applications.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom